Evidence map›Paper›PMID 38592343›Full record

ArticleJournal of clinical medicine2024

Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX-Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective-Prospective Study.

Antonio Coppola, Gianna Franca Rivolta, Gabriele Quintavalle, Annalisa Matichecchia, Federica Riccardi, Rossana Rossi, Anna Benegiamo, Paola Ranalli, Valeria Coluccio, Annarita Tagliaferri

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Extended Half-Life Factor Concentrates in Haemophilia Treatment.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Antonio CoppolaRegional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, 43126 Parma, Italy.ORCID 0000-0003-3697-706X
Gianna Franca RivoltaRegional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, 43126 Parma, Italy.
Gabriele QuintavalleRegional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, 43126 Parma, Italy.ORCID 0000-0002-1999-4485
Annalisa MatichecchiaRegional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, 43126 Parma, Italy.ORCID 0000-0002-5154-4636
Federica RiccardiRegional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, 43126 Parma, Italy.ORCID 0000-0002-6308-6054
Rossana RossiCoagulation Laboratory, Diagnostic Department, University Hospital of Parma, 43126 Parma, Italy.
Anna BenegiamoCoagulation Laboratory, Diagnostic Department, University Hospital of Parma, 43126 Parma, Italy.
Paola RanalliHemophilia and Blood Rare Disease Center, Oncohematology Department, Spirito Santo Civil Hospital, 65124 Pescara, Italy.
Valeria ColuccioHematology Unit, University Hospital of Modena, 41124 Modena, Italy.
Annarita TagliaferriRegional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, 43126 Parma, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

extended half-life FIX concentrateshemophilia Bprophylaxistreatment outcomestreatment personalization

Identifiers

PMID38592343
PMCPMC10933977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.